-
Je něco špatně v tomto záznamu ?
Návrh štruktúry, syntéza a biologická aktivita nových karbamátových inhibítorov cholínesteráz
[Design, synthesis and biological activity of new carbamate cholinesterase inhibitors]
Lucia Ungvarská Maľučká, Jozef Csöllei
Jazyk slovenština Země Česko
- MeSH
- acetylcholinesterasa MeSH
- Alzheimerova nemoc diagnóza farmakoterapie patologie MeSH
- butyrylcholinesterasa MeSH
- cholinesterasové inhibitory * chemie farmakologie terapeutické užití MeSH
- karbamáty chemie terapeutické užití MeSH
- lidé MeSH
- rivastigmin analogy a deriváty terapeutické užití MeSH
- vyvíjení léků metody MeSH
- Check Tag
- lidé MeSH
The work deals with the design, synthesis and biolog-icalactivityofnewcarbamatecholinesteraseinhibitors.Itis focused on selected syntheses of new carbamate deriva-tives, which were tested for their anticholinesterase activi-ty against acetylcholinesterase as well as butyrylcholines-terase. Despite various theories in the pathogenesis of Alz-heimer's disease, drugs that can inhibit these two enzymes still represent the major approach to the treatment of this neurodegenerative disease. Many of the newly synthesized compounds have unique chemical structure. Recently, the approach to the synthesis of new cholinesterase inhibitors has focused on the preparation of potential drugs, contain-ing in their chemical structure fragments of already known drugs, commonly used in the pharmacotherapy of Alzhei-mer's disease, but also other diseases. The aim of prepar-ing these compounds is to affect several biological systems simultaneously. These multipotent compounds have been termed "multi-target-directed ligands"; the molecules of drugs used to treat Alzheimer's disease always contain a pharmacophore acting as a cholinesterase inhibitor, which represents the mainstay of therapy
Design, synthesis and biological activity of new carbamate cholinesterase inhibitors
Citace poskytuje Crossref.org
Literatura
- 000
- 00000naa a2200000 a 4500
- 001
- bmc23007888
- 003
- CZ-PrNML
- 005
- 20240220143411.0
- 007
- ta
- 008
- 230615s2022 xr a f 000 0|slo||
- 009
- AR
- 024 7_
- $a 10.54779/chl20220372 $2 doi
- 040 __
- $a ABA008 $d ABA008 $e AACR2 $b cze
- 041 0_
- $a slo $b eng
- 044 __
- $a xr
- 100 1_
- $a Ungvarská Maľučká, Lucia $7 xx0159249 $u Univerzita veterinárskeho lekárstva a farmácie v Košiciach, Katedra chémie, biochémie abiofyziky, Košice, Slovenská republika $u Masarykova univerzita, Farmaceutická fakulta, Ústav chemických léčiv, Brno, Česká republika
- 245 10
- $a Návrh štruktúry, syntéza a biologická aktivita nových karbamátových inhibítorov cholínesteráz / $c Lucia Ungvarská Maľučká, Jozef Csöllei
- 246 31
- $a Design, synthesis and biological activity of new carbamate cholinesterase inhibitors
- 504 __
- $a Literatura
- 520 3_
- $a The work deals with the design, synthesis and biolog-icalactivityofnewcarbamatecholinesteraseinhibitors.Itis focused on selected syntheses of new carbamate deriva-tives, which were tested for their anticholinesterase activi-ty against acetylcholinesterase as well as butyrylcholines-terase. Despite various theories in the pathogenesis of Alz-heimer's disease, drugs that can inhibit these two enzymes still represent the major approach to the treatment of this neurodegenerative disease. Many of the newly synthesized compounds have unique chemical structure. Recently, the approach to the synthesis of new cholinesterase inhibitors has focused on the preparation of potential drugs, contain-ing in their chemical structure fragments of already known drugs, commonly used in the pharmacotherapy of Alzhei-mer's disease, but also other diseases. The aim of prepar-ing these compounds is to affect several biological systems simultaneously. These multipotent compounds have been termed "multi-target-directed ligands"; the molecules of drugs used to treat Alzheimer's disease always contain a pharmacophore acting as a cholinesterase inhibitor, which represents the mainstay of therapy
- 650 17
- $a cholinesterasové inhibitory $x chemie $x farmakologie $x terapeutické užití $7 D002800 $2 czmesh
- 650 _7
- $a karbamáty $x chemie $x terapeutické užití $7 D002219 $2 czmesh
- 650 _7
- $a Alzheimerova nemoc $x diagnóza $x farmakoterapie $x patologie $7 D000544 $2 czmesh
- 650 _7
- $a acetylcholinesterasa $7 D000110 $2 czmesh
- 650 _7
- $a butyrylcholinesterasa $7 D002091 $2 czmesh
- 650 _7
- $a rivastigmin $x analogy a deriváty $x terapeutické užití $7 D000068836 $2 czmesh
- 650 _7
- $a lidé $7 D006801 $2 czmesh
- 650 _7
- $a vyvíjení léků $x metody $7 D000076722 $2 czmesh
- 700 1_
- $a Csöllei, Jozef, $d 1950- $7 ola2002151504 $u Masarykova univerzita, Farmaceutická fakulta, Ústav chemických léčiv, Brno, Česká republika
- 773 0_
- $t Chemické listy $x 0009-2770 $g Roč. 116, č. 6 (2022), s. 372−380 $w MED00011010
- 856 41
- $u http://www.chemicke-listy.cz/ojs3/index.php/chemicke-listy/Archives $y stránka časopisu
- 910 __
- $a ABA008 $b B 1918 $c 395 $y p $z 0
- 990 __
- $a 20230531121729 $b ABA008
- 991 __
- $a 20240220143408 $b ABA008
- 999 __
- $a ok $b bmc $g 1945261 $s 1194127
- BAS __
- $a 3
- BMC __
- $a 2022 $b 116 $c 6 $d 372−380 $i 0009-2770 $m Chemické listy $x MED00011010
- LZP __
- $c NLK183 $d 20231013 $a NLK 2023-05/iš